Results 1 to 10 of about 1,254,012 (356)

Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas

Acta Oncologica
Background and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this ...
Lisa Millgård Sagberg, Øyvind Salvesen, Asgeir Store Jakola, Erik Thurin, Eddie de Dios, Noah L.A. Nawabi, John L. Kilgallon, Joshua D. Bernstock, Vasileios K. Kavouridis, Timothy R. Smith, Ole Solheim   +10 more
doaj   +4 more sources

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer [PDF]

Journal of Clinical Oncology
PURPOSE: Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer.
Buyse, Marc E, Carducci, Michael A, Dearnaley, David P, Godolphin, Peter, Goto, Takayuki, Gravis, Gwenaelle, Guo, Siyuan, Halabi, Susan, Hussain, Maha, James, Nick, Morris, Michael J, Roy, Akash, Rydzewska, Larysa, Smith, Matthew R, STOPCAP/ICECaP, Collaboration, Sweeney, Christopher, Tangen, Catherine, Thompson, Ian, Tierney, Jayne F, Verhagen, Paul, Xie, Wanling   +20 more
core   +4 more sources

Comparison of PFS-OS between two treatment methods (surgery and then chemotherapy compared with neoadjuvant and then surgery) in patients with endometrial cancer: a retrospective study [PDF]

Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2023
Introduction: Endometrial cancer is one of the common diseases among women, which causes the death of many women in the world every year. The survival of patients and their response to treatment is determined based on clinical conditions and the stage of
Narjes Afrooz, Setare Nasiri, Soheila Aminimoghaddam   +2 more
doaj   +1 more source

High-dose-rate endobronchial brachytherapy in the management of advanced lung cancer - comparison according to the presence of lung atelectasis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2021
Introduction/Objective. Locally advanced lung cancer is often accompanied by atelectasis of either a part or the entire lung. The aim of this study was to establish the benefits of brachytherapy on the patients’ quality of life, the length of the ...
Bojović Marko, Lalić Nensi, Bošković Tatjana, Ilić Miroslav, Ivanov Olivera, Ličina Jelena, Nikolin Borislava, Kalember Sandro   +7 more
doaj   +1 more source

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer

European Urology Open Science, 2023
The PROpel trial assessed the combination of olaparib + abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer ...
Giuseppe Fallara, Daniele Robesti, Daniele Raggi, Francesco Montorsi, Andrea Necchi, Matthew R. Cooperberg, Bernard Malavaud, Guillaume Ploussard, Alberto Martini   +8 more
doaj   +1 more source

Prognostic impact of p16 and p53 gene expressions in stage 1a epithelial ovarian cancer [PDF]

Obstetrics & Gynecology Science, 2020
Objective Epithelial ovarian cancer (EOC) is rarely detected at stage 1a. Most of the patients have a good prognosis and there are limited factors that affect their survival. In the present study, we evaluated the p16 and p53 gene expressions of stage 1a
Emre Günakan, Yusuf Aytaç Tohma, Latife Atasoy Karakaş, Hüseyin Akıllı, Asuman Nihan Haberal, Ali Ayhan   +5 more
doaj   +1 more source

Progression‐free survival in oncology: Caveat emptor! [PDF]

Basic & Clinical Pharmacology & Toxicology, 2018
AbstractOverall survival (OS) is the undisputed gold standard efficacy end‐point in cancer drug trials. It is with growing concern that we observe how progression‐free survival (PFS) gains ground as surrogate end‐point in its place. PFS has appeal because it is resource‐efficient, but it has severe shortcomings.
Bergmann, Troels K, Christensen, Mette Marie H, Henriksen, Daniel, Haastrup, Maija Bruun, Damkier, Per   +4 more
openaire   +3 more sources

An Audit Strategy for Progression-Free Survival [PDF]

Biometrics, 2011
In randomized clinical trials, the use of potentially subjective endpoints has led to frequent use of blinded independent central review (BICR) and event adjudication committees to reduce possible bias in treatment effect estimators based on local evaluations (LE). In oncology trials, progression-free survival (PFS) is one such endpoint.
Dodd, Lori E., Korn, Edward L., Freidlin, Boris, Gray, Robert, Bhattacharya, Suman   +4 more
openaire   +3 more sources

Evaluating the Association between Clinical Characteristics with Progression-Free Survival and 3-Year Survival in Patients with Epithelial Ovarian Cancer

Indonesian Journal of Cancer, 2021
Background: This study was conducted to determine the association between clinical characteristics, progression-free survival (PFS), and 3-year survival in patients with epithelial ovarian cancer who underwent surgery in 2016-2017 at RSUD Dr.
Brahmana Askandar Tjokroprawiro, Sonny Fadli, Budiono   +2 more
doaj   +1 more source

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort

Medicina, 2022
Background and Objectives: For stage IIIb–IV ovarian cancer, bevacizumab-containing treatment is considered the standard of care. The purpose of this study was to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as a ...
Irena Conic, Bojan Nedovic, Slavica Stojnev, Ilinka Todorovska, Aleksandra Dimitrijevic, Miljan Krstic, Ivana Djordjevic, Biljana Djordjevic   +7 more
doaj   +1 more source